231 - Industry-Supported Presentation Theater - Tardive Dyskinesia in Long-Term Care Residents: Screening for Movements, Assessing Impact, and Treatment Considerations - Supported by Teva Pharmaceuticals USA, Inc.

Meals are served on a first-come, first-serve basis.

This product theater will provide information on tardive dyskinesia (TD) in long-term care (LTC) facilities and review the efficacy and safety data from the pivotal and the long-term open-label extension studies for AUSTEDO. The participant will learn how the impact of TD affects both residents and staff at LTC facilities, how routinely observing and monitoring residents for abnormal movements can inform treatment decisions, and how to distinguish TD from drug-induced parkinsonism in LTC residents. Also, the appropriate dosing and titration of AUSTEDO XR will be discussed. At the end of the session, the participant will be invited to take part in a Q&A session.

Supported by Teva Pharmaceuticals USA, Inc.